90 related articles for article (PubMed ID: 22534465)
1. Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT scans for diagnosing ovarian cancer recurrence.
Kitajima K; Ueno Y; Suzuki K; Kita M; Ebina Y; Yamada H; Senda M; Maeda T; Sugimura K
Eur J Radiol; 2012 Nov; 81(11):3557-62. PubMed ID: 22534465
[TBL] [Abstract][Full Text] [Related]
2. Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT studies for the diagnosis of uterine cancer recurrence.
Kitajima K; Suzuki K; Nakamoto Y; Onishi Y; Sakamoto S; Senda M; Kita M; Sugimura K
Eur J Nucl Med Mol Imaging; 2010 Aug; 37(8):1490-8. PubMed ID: 20386901
[TBL] [Abstract][Full Text] [Related]
3. Detection of recurrent colorectal cancer by 18F-FDG PET/CT comparison with contrast enhanced CT scan.
Chiewvit S; Jiranantanakorn T; Apisarnthanarak P; Kanchaanapiboon P; Hannanthawiwat C; Ubolnuch K; Phongsawat N; Chiewvit P
J Med Assoc Thai; 2013 Jun; 96(6):703-8. PubMed ID: 23951828
[TBL] [Abstract][Full Text] [Related]
4. Predictive role of post-treatment [18F]FDG PET/CT in patients with uterine cervical cancer.
Chung HH; Kim JW; Kang KW; Park NH; Song YS; Chung JK; Kang SB
Eur J Radiol; 2012 Aug; 81(8):e817-22. PubMed ID: 22595504
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of PET/CT is similar to that of conventional MRI and even better for detecting small peritoneal implants in patients with recurrent ovarian cancer.
Sanli Y; Turkmen C; Bakir B; Iyibozkurt C; Ozel S; Has D; Yilmaz E; Topuz S; Yavuz E; Unal SN; Mudun A
Nucl Med Commun; 2012 May; 33(5):509-15. PubMed ID: 22357440
[TBL] [Abstract][Full Text] [Related]
6. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer.
Hebel CB; Behrendt FF; Heinzel A; Krohn T; Mottaghy FM; Bauerschlag DO; Verburg FA
Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010
[TBL] [Abstract][Full Text] [Related]
7. Indeterminate pulmonary nodules on CT images in breast cancer patient: the additional value of 18F-FDG PET/CT.
Evangelista L; Panunzio A; Cervino AR; Vinante L; Al-Nahhas A; Rubello D; Muzzio PC; Polverosi R
J Med Imaging Radiat Oncol; 2012 Aug; 56(4):417-24. PubMed ID: 22883649
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus.
Guo H; Zhu H; Xi Y; Zhang B; Li L; Huang Y; Zhang J; Fu Z; Yang G; Yuan S; Yu J
J Nucl Med; 2007 Aug; 48(8):1251-8. PubMed ID: 17631554
[TBL] [Abstract][Full Text] [Related]
9. Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice?
Soyka JD; Veit-Haibach P; Strobel K; Breitenstein S; Tschopp A; Mende KA; Lago MP; Hany TF
J Nucl Med; 2008 Mar; 49(3):354-61. PubMed ID: 18287263
[TBL] [Abstract][Full Text] [Related]
10. Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy.
Satoh Y; Nambu A; Onishi H; Sawada E; Tominaga L; Kuriyama K; Komiyama T; Marino K; Aoki S; Araya M; Saito R; Maehata Y; Oguri M; Araki T
Eur J Radiol; 2012 Nov; 81(11):3530-4. PubMed ID: 22178287
[TBL] [Abstract][Full Text] [Related]
11. Clinical value of manual fusion of PET and CT images in patients with suspected recurrent colorectal cancer.
Nakamoto Y; Sakamoto S; Okada T; Senda M; Higashi T; Saga T; Togashi K
AJR Am J Roentgenol; 2007 Jan; 188(1):257-67. PubMed ID: 17179375
[TBL] [Abstract][Full Text] [Related]
12. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.
Goerres GW; Stupp R; Barghouth G; Hany TF; Pestalozzi B; Dizendorf E; Schnyder P; Luthi F; von Schulthess GK; Leyvraz S
Eur J Nucl Med Mol Imaging; 2005 Feb; 32(2):153-62. PubMed ID: 15690223
[TBL] [Abstract][Full Text] [Related]
13. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer.
Dirisamer A; Halpern BS; Flöry D; Wolf F; Beheshti M; Mayerhoefer ME; Langsteger W
Eur J Radiol; 2010 Feb; 73(2):294-9. PubMed ID: 19181468
[TBL] [Abstract][Full Text] [Related]
14. A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET/CT and staging laparoscopy.
Fagotti A; Fanfani F; Rossitto C; Lorusso D; De Gaetano AM; Giordano A; Vizzielli G; Scambia G
Oncology; 2008; 75(3-4):152-8. PubMed ID: 18827492
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology.
Castellucci P; Perrone AM; Picchio M; Ghi T; Farsad M; Nanni C; Messa C; Meriggiola MC; Pelusi G; Al-Nahhas A; Rubello D; Fazio F; Fanti S
Nucl Med Commun; 2007 Aug; 28(8):589-95. PubMed ID: 17625380
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 18F-FDG positron emission tomography/computed tomography and computed tomography in patients with already-treated breast cancer: diagnostic and prognostic implications.
Evangelista L; Baretta Z; Vinante L; Bezzon E; De Carolis V; Cervino AR; Gregianin M; Ghiotto C; Saladini G; Pomerri F; Muzzio PC
Q J Nucl Med Mol Imaging; 2012 Aug; 56(4):375-84. PubMed ID: 23013667
[TBL] [Abstract][Full Text] [Related]
17. Prospective evaluation of CECT and 18F-FDG-PET/CT in detection of hepatic metastases.
D'souza MM; Sharma R; Mondal A; Jaimini A; Tripathi M; Saw SK; Singh D; Mishra A; Tripathi RP
Nucl Med Commun; 2009 Feb; 30(2):117-25. PubMed ID: 19057427
[TBL] [Abstract][Full Text] [Related]
18. Comparison of physical examination and fluorodeoxyglucose positron emission tomography/computed tomography 4-6 months after radiotherapy to assess residual head-and-neck cancer.
Zundel MT; Michel MA; Schultz CJ; Maheshwari M; Wong SJ; Campbell BH; Massey BL; Blumin J; Wilson JF; Wang D
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e825-32. PubMed ID: 21300450
[TBL] [Abstract][Full Text] [Related]
19. Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases.
Seo HJ; Kim MJ; Lee JD; Chung WS; Kim YE
Invest Radiol; 2011 Sep; 46(9):548-55. PubMed ID: 21577131
[TBL] [Abstract][Full Text] [Related]
20. To Enhance or Not to Enhance? The Role of Contrast Medium
Massollo M; Fiz F; Bottoni G; Ugolini M; Paparo F; Puppo C; Provinciali N; Iacozzi M; Altrinetti V; Cistaro A; Cabria M; DeCensi A; Treglia G; Piccardo A
Medicina (Kaunas); 2021 Jun; 57(6):. PubMed ID: 34206116
[No Abstract] [Full Text] [Related]
[Next] [New Search]
